首页>
外文期刊>Prescrire international
>glibenclamide oral suspension (amglidia0) and neonatal diabetes Marketing authorisation and an appropriate ready-to-use form are welcome developments
【24h】
glibenclamide oral suspension (amglidia0) and neonatal diabetes Marketing authorisation and an appropriate ready-to-use form are welcome developments
展开▼
机译：glibenclamide oral suspension (amglidia0) and neonatal diabetes Marketing authorisation and an appropriate ready-to-use form are welcome developments
Glibenclamide therapy enables newborns, infants and children with neonatal diabetes caused by certain gene mutations to stop insulin injections without compromising gly-caemic control. It may also alleviate certain neuropsychiatric disorders.The data are limited however. A ready-to-use oral suspension of glibenclamide makes the drug easier to give to children who have difficulty swallowing tablets. Glibenclamide can cause potentially severe hypoglycaemia.
展开▼
